Nemtabrutinib + CAR T Therapy for Mantle Cell Lymphoma

This trial explores a new combination treatment for individuals with mantle cell lymphoma that has returned or not responded to previous therapies. The treatment includes nemtabrutinib, which aims to stop cancer growth, and CAR T-cell therapy, which uses modified immune cells to attack the cancer. The goal is to determine the safety and effectiveness of this combination. This trial might suit someone diagnosed with relapsed or hard-to-treat mantle cell lymphoma.

As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in therapy.

The trial requires a washout period (time without taking certain medications) for drugs that are P-glycoprotein substrates with a narrow therapeutic index, CYP3A strong inducers, and CYP3A strong inhibitors. You may need to stop these medications before joining the trial.

Research shows that nemtabrutinib, when combined with brexucabtagene autoleucel (brexu-cel), may be safe for patients with relapsed or hard-to-treat mantle cell lymphoma. Studies have found that brexu-cel generally maintains a good safety record, with most side effects being manageable and serious problems rare. For instance, one study found that only 3% of patients experienced late-onset side effects with brexu-cel.

Researchers are excited about the combination of nemtabrutinib and brexucabtagene autoleucel (brexu-cel) for treating Mantle Cell Lymphoma because of its unique approach. Unlike standard treatments, which often rely on chemotherapy and targeted therapies like BTK inhibitors, this combination leverages a novel mechanism involving CAR T-cell therapy, which uses genetically engineered T-cells to target and destroy cancer cells more precisely. Additionally, nemtabrutinib is an oral BTK inhibitor that may enhance the effectiveness of CAR T-cell therapy by keeping the cancer cells in check before and after the T-cell infusion. This dual-action strategy could potentially improve outcomes for patients with this aggressive form of lymphoma.

This trial will evaluate the combination of Nemtabrutinib and brexucabtagene autoleucel (brexu-cel) for treating mantle cell lymphoma. Studies have shown that brexucabtagene autoleucel, a type of CAR T-cell therapy, effectively treats relapsed or refractory mantle cell lymphoma. In one study, 87% of patients responded to this treatment, with 62% showing no detectable cancer afterward. Another analysis found a 93% overall response rate and a 67% complete response rate with this therapy. Although less information exists on nemtabrutinib, it is a BTK inhibitor that may help stop cancer cells from growing. Combining it with brexu-cel in this trial aims to improve treatment effectiveness by attacking cancer cells in different ways.¹⁶⁷⁸⁹